Japanese Simple Chinese Traditional Chinese Korean 

Conference Menu

Current Event 

Overview
Register
Day 1
Day 2
Day 3
PDF Download
Short Course
Delegate List
Posters
Hotel & Travel
Sponsor & Exhibits
Press Pass 
Request Brochure 
Archives 

Chemical Computing Group 

 

OpenEye_Vertical 

Reaction Biology 

Schrodinger 

Vlife Logo 

Aurigene
Intelligent Pharma 

Bio-IT-Word_logo 

Gen 

Insight Pharma Reports 

Science AAAS logo 

The Scientist 

chemical biology 

PharmaVoice 

ISCB 

Markets and Markets logo 

Reports and Reports 

CanBiotech logo 

Pharmaphorum 

 

Pharm Cast 

SelectScience logo 

DVDs 

Therapeutic Target Space:
Methods for Druggability Assessment
 


CHI's Structure-Based Drug Design Conference

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

Final Days to Register! 


Cambridge Healthtech Institute’s Eleventh Annual Structure-Based Drug Design conference brings to focus the latest development in computational technology for drug discovery, and puts structure-based molecular approaches into the perspective of targeted therapeutics.

Conference Highlights: 

  • Protein Flexibility
  • Fully Synthetic Protein-Protein Interaction Inhibitor
  • Fragment-to-Lead Optimization
  • High Performance Computing and Collaborative Drug Design
  • State-of-the-Art Molecular Dynamics Simulations

 

Keynote Speaker: 

Millisecond-Long Molecular Dynamics Simulations of Proteins on a Special-Purpose Machine

David ShawDavid E. Shaw, Ph.D., Chief Scientist, D. E. Shaw Research

David E. Shaw serves as chief scientist of D. E. Shaw Research and as a senior research fellow at the Center for Computational Biology and Bioinformatics at Columbia University. He received his Ph.D. from Stanford University in 1980, served on the faculty of the Computer Science Department at Columbia until 1986, and founded the D. E. Shaw group in 1988. Since 2001, Dr. Shaw has devoted most of his time to hands-on research in the field of computational biochemistry. His lab is currently involved in the development of new algorithms and machine architectures for high-speed molecular dynamics simulations of biological macromolecules, and in the application of such simulations to basic scientific research and computer-assisted drug design.

Dr. Shaw was appointed to the President’s Council of Advisors on Science and Technology by President Clinton in 1994, and again by President Obama in 2009. He is a fellow of the American Academy of Arts and Sciences and of the American Association for the Advancement of Science.

PodcastAnton: Molecular Dynamics Simulation for Drug Design 

 

 

Dinner Short Course: 

June 8, 2011

 

Identification of Druggable Sites for Protein-Protein Interaction Targets 

 

Scientific Advisory Board: 

José Duca, Ph.D., Head, Computer Aided Drug Discovery, Novartis 

Alan C. Rigby, Ph.D., Vice President, Research, Computational Discovery, ImClone Systems-A wholly-owned subsidiary of Eli Lilly and Company 

Tomi Sawyer, Ph.D., CSO, Aileron Therapeutics, Inc.; Editor-in-Chief, Chemical Biology & Drug Design 

Woody Sherman, Ph.D., Vice President, Applications Science, Schrödinger, Inc. 

Gergely Toth, Ph.D., Research Fellow, Department of Chemistry, University of Cambridge 

Marcel Verdonk, Ph.D., Director, Computational Chemistry and Informatics, Astex Therapeutics Ltd. 

Pat Walters, Ph.D., Senior Research Fellow, Vertex Pharmaceuticals, Inc. 

Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group 


 

Co-Located With:
Next-Gen Kinase Inhibitors 


By Series:
By Region: